Bicycle Therapeutics PLC Form 4 insider transactions

Bicycle Therapeutics PLC director Roger D. Dansey received an award of 3,032 restricted share units and 6,065 stock options.

Bicycle Therapeutics PLC Director Gregory Paul Winter was granted 9,500 restricted share units and 19,000 stock options, vesting throughout 2026.

Bicycle Therapeutics PLC director Herve Hoppenot was granted 3,032 restricted share units and options to purchase 6,065 ordinary shares, effective January 2, 2026.

Bicycle Therapeutics PLC director Janice Bourque was granted 9,500 restricted share units and options to purchase 19,000 ordinary shares.

Bicycle Therapeutics director Jose-Carlos Gutierrez-Ramos acquired 9,500 restricted share units and 19,000 stock options.

Robert Charles Swanton, a Director at Bicycle Therapeutics PLC, was granted 3,726 restricted share units and options to purchase 7,453 ordinary shares.

Baker Bros. Advisors LP and affiliated entities reported the acquisition of restricted share units and share options in Bicycle Therapeutics PLC for director Felix J. Baker.

Bicycle Therapeutics CEO Kevin Lee sold ordinary shares to cover statutory tax withholding obligations related to restricted stock unit vesting, not as a discretionary sale.

Bicycle Therapeutics CTO Michael Skynner sold shares to cover statutory tax withholding obligations related to restricted stock unit vesting, not as a discretionary sale.

Bicycle Therapeutics' Chief Operating Officer, Alistair Milnes, sold ordinary shares to cover statutory tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, sold 723 ordinary shares in non-discretionary transactions to cover tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics CFO Alethia Young sold 482 ordinary shares on October 2, 2025, for tax obligations and under a pre-arranged 10b5-1 trading plan.

Bicycle Therapeutics' Chief Accounting Officer, Travis Thompson, sold shares to cover tax obligations from restricted stock unit vesting.

Bicycle Therapeutics Director Robert Charles Swanton sold 102 ordinary shares for $8.55 each, as part of a pre-arranged 10b5-1 trading plan.

Bicycle Therapeutics PLC Director Herve Hoppenot was granted 12,500 restricted share units and options for 25,000 ordinary shares.

Bicycle Therapeutics Director Roger D. Dansey was granted 12,500 restricted share units and options for 25,000 ordinary shares.

Bicycle Therapeutics PLC director Robert Charles Swanton was granted 12,500 restricted share units and 25,000 stock options.

Bicycle Therapeutics PLC's CEO, Kevin Lee, sold 5,461 ordinary shares across two transactions in early July 2025, solely to satisfy statutory tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics PLC's Chief Technology Officer, Michael Skynner, sold a total of 1,791 ordinary shares in non-discretionary 'sell to cover' transactions to satisfy tax withholding obligations.

Bicycle Therapeutics' Chief Operating Officer, Alistair Milnes, sold a total of 2,115 ordinary shares across two transactions in early July 2025 to satisfy tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics' Chief Product & Supply Chain Officer, Michael Charles Ferguson Hannay, sold a total of 722 ordinary shares to cover statutory tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics PLC's Chief Accounting Officer, Travis Alvin Thompson, sold a total of 306 ordinary shares in non-discretionary transactions to cover tax withholding obligations related to restricted stock unit vesting.

Bicycle Therapeutics' Chief Financial Officer, Alethia Young, sold 204 ordinary shares at a weighted average price of $7.09 to cover statutory tax withholding obligations related to restricted stock unit vesting.

Alethia Young, CFO of Bicycle Therapeutics PLC, sold 215 ordinary shares on April 2, 2025, to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units.

Michael Skynner, Chief Technology Officer of Bicycle Therapeutics PLC, sold shares to cover statutory tax withholding obligations related to vesting restricted stock units.

Bicycle Therapeutics CEO Kevin Lee sold shares on April 2nd and 3rd, 2025, to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units.

Alistair Milnes, COO of Bicycle Therapeutics PLC, sold shares to cover statutory tax withholding obligations related to the vesting and settlement of restricted stock units.

Michael Charles Ferguson Hannay, Chief Product & Supply Chain Officer of Bicycle Therapeutics PLC, sold shares to cover statutory tax withholding obligations.

Travis Alvin Thompson, Chief Accounting Officer of Bicycle Therapeutics PLC, sold shares to cover statutory tax withholding obligations related to vesting and settlement of restricted stock units.

Director Alessandro Riva acquired restricted share units and stock options in Bicycle Therapeutics PLC on March 25, 2025.